苑东生物(688513) - 2025 Q4 - 年度业绩

Revenue Performance - Total revenue for 2025 was CNY 133,139.76 million, a decrease of 1.36% compared to the previous year[3] - The company reported a decrease in total revenue due to the impact of the tenth batch of national centralized procurement, but profit growth remained robust[6] Profitability - Net profit attributable to shareholders of the parent company reached CNY 28,324.83 million, an increase of 18.89% year-on-year[3] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was CNY 20,624.39 million, up 18.01% from the previous year[3] - Basic earnings per share increased to CNY 1.63, reflecting a growth of 19.85%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 379,885.73 million, an increase of 11.73% from the beginning of the period[3] - Shareholders' equity attributable to the parent company was CNY 293,202.71 million, up 8.68% from the beginning of the period[3] Operational Measures - The company implemented measures to optimize revenue structure and enhance cost control, which helped mitigate the impact of the national centralized procurement policy[6] Return on Assets - The weighted average return on net assets increased to 10.09%, up 0.95 percentage points from the previous year[3] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be confirmed in the annual report[4]